Akari Therapeutics Announces Regulatory Progress Following FDA Meeting

Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON, September 21, 2017 (GLOBE NEWSWIRE) — Akari Therapeutics (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, announces that, following advice from a recent FDA Type B End […]

Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

NEW YORK and LONDON, September 19, 2017 – Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday September 26, 2017 in New York City. The presentation […]

Akari Therapeutics Announces Appointment of David Horn Solomon as CEO

NEW YORK and LONDON – Akari Therapeutics (NASDAQ:AKTX, is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive officer (CEO), effective August 28, 2017. “I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with […]

Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference

NEW YORK and LONDON, August 10, 2017 (GLOBE NEWSWIRE) — Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson, Chief Operations Officer, and Dr. Wynne Weston-Davies, Medical Director, will present at the 37th Annual Canaccord Genuity Growth Conference on August 10th, 2017, in Boston, Massachusetts. The company is scheduled […]

Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association

NEW YORK and LONDON, June 23, 2017 — Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain containing data for the four patients, to date, who have completed its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal […]